Skip to main content
David Camidge, MD, Oncology, Aurora, CO, University of Colorado Hospital

DavidRCamidgeMD

Oncology • Aurora, CO

Associate Professor, Medicine, University of Colorado School of Medicine

Join to view full profile

Dr. Camidge is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Camidge's full profile

Already have an account?

Summary

  • Dr Camidge is the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado. His focus is in Thoracic Malignancies and Developmental Therapeutics (Phase I studies). In 2012, he was announced as the recipient of the 5th Bonnie J. Addario Lectureship as a ‘Luminary in the quest to eradicate lung cancer.’ In 2013, he became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being ‘one of the leading minds in lung cancer today.’ In 2015, he became the inaugural holder of the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center.
    Dr Camidge is the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium and a member of the National Comprehensive Cancer Network Lung Cancer Committee.
    In addition to training Fellows through the CU ACGME Medical Oncology Fellowship, Dr Camidge is also the Director of the CU Senior Thoracic Oncology Clinical and Translational Research Fellowship - a unique ‘finishing school’ in advanced cancer clinical research for US and International Graduates who have already completed their basic Medical Oncology training. Through these two programs, Dr Camidge has mentored a consistent series of outstanding early career medical oncologists. In 2014, he was nationally recognized by The Quality of Life Center at Claremont University in California as an ‘Exemplary mentor in the positive development of junior colleagues in the profession.’

Education & Training

  • Oxford University Medical School
    Oxford University Medical SchoolClass of 1995, MD

Certifications & Licensure

  • CO State Medical License
    CO State Medical License 2008 - 2025

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Brigatinib Versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer  
    D Ross Camidge, Scott N Gettinger, Alexander Spira, The New England Journal of Medicine
  • Correlation of Extent of ALK FISH Positivity and Crizotinib Efficacy in Three Prospective Studies of ALK-Positive Patients with Non-Small Cell Lung Cancer  
    D R Camidge, A T Shaw, Annals of Oncology

Lectures

  • Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mu... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
    Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK MutationMay 9th, 2018

Hospital Affiliations

Dr. David Camidge, Dr. David Camidge, MD, Dr. D Camidge, Dr. David R Camidge